Literature DB >> 25362656

Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis.

Monique E Hinchcliff1, Jennifer L Beaumont2, Mary A Carns2, Sofia Podlusky2, Krishna Thavarajah2, John Varga2, David Cella2, Rowland W Chang2.   

Abstract

OBJECTIVE: To assess the sensitivity of the Patient-Reported Outcomes Measurement Information System 29-item Health Profile (PROMIS-29) and the Functional Assessment of Chronic Illness Therapy-Dyspnea 10-item short form (FACIT-Dyspnea) for measuring change in health status and dyspnea in systemic sclerosis (SSc).
METHODS: One hundred patients with SSc completed the PROMIS-29, FACIT-Dyspnea, and traditional instruments [Medical Research Council Dyspnea Score, St. George's Respiratory Questionnaire (SGRQ), Health Assessment Questionnaire-Disability Index (HAQ-DI), and Medical Outcomes Study Short Form-36 (SF-36)] at baseline and 1-year visits. PROMIS-29, FACIT-Dyspnea, and traditional instrument change scores were compared across composite modified Medsger Disease Severity and modified Rodnan Skin score (mRSS) change groups.
RESULTS: Moderately high Spearman correlation coefficients were observed between FACIT-Dyspnea and SGRQ (r = 0.57), FACIT-Dyspnea functional limitations and SF-36 physical component summary (PCS; r = 0.51), PROMIS-29 physical functioning and HAQ-DI (r = 0.50), and SF-36 PCS (r = 0.52) change scores. In most validity comparisons, PROMIS-29, FACIT-Dyspnea, HAQ-DI, and SF-36 scores performed similarly. While PROMIS-29 covers more content areas than SF-36 (e.g., sleep), it may do so at the expense of responsiveness of its 4-item physical function scale as compared to the multiitem-derived SF-36 PCS. Statistically significant increases in SF-36 role physical (p = 0.01) and physical component scale (p = 0.016), but not PROMIS-29, were observed in patients with mRSS improvement.
CONCLUSION: PROMIS-29 and FACIT-Dyspnea are valid instruments to measure health status and dyspnea in patients with SSc. In physical function assessment, longer PROMIS short forms or computer adaptive testing should be considered to improve responsiveness to the effect of skin disease changes on physical function in patients with SSc.

Entities:  

Keywords:  FACIT; HEALTH STATUS; PROMIS; SEVERITY INDEX; SYSTEMIC SCLEROSIS

Mesh:

Year:  2014        PMID: 25362656      PMCID: PMC4480645          DOI: 10.3899/jrheum.140143

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  22 in total

1.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

3.  A brief symptom index for advanced lung cancer.

Authors:  Susan Yount; Jennifer Beaumont; Sarah Rosenbloom; David Cella; Jyoti Patel; Thomas Hensing; Paul B Jacobsen; Karen Syrjala; Amy P Abernethy
Journal:  Clin Lung Cancer       Date:  2011-05-23       Impact factor: 4.785

4.  Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic.

Authors:  Dinesh Khanna; Paul Maranian; Nan Rothrock; David Cella; Richard Gershon; Puja P Khanna; Brennan Spiegel; Daniel E Furst; Phil J Clements; Amber Bechtel; Ron D Hays
Journal:  Value Health       Date:  2011-10-22       Impact factor: 5.725

5.  A disease severity scale for systemic sclerosis: development and testing.

Authors:  T A Medsger; A J Silman; V D Steen; C M Black; A Akesson; P A Bacon; C A Harris; S Jablonska; M I Jayson; S A Jimenez; T Krieg; E C Leroy; P J Maddison; M L Russell; R K Schachter; F A Wollheim; H Zacharaie
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

8.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

Review 9.  Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

10.  Text data extraction for a prospective, research-focused data mart: implementation and validation.

Authors:  Monique Hinchcliff; Eric Just; Sofia Podlusky; John Varga; Rowland W Chang; Warren A Kibbe
Journal:  BMC Med Inform Decis Mak       Date:  2012-09-13       Impact factor: 2.796

View more
  16 in total

1.  Prediction of Oswestry Disability Index (ODI) using PROMIS-29 in a national sample of lumbar spine surgery patients.

Authors:  Jacquelyn S Pennings; Clinton J Devin; Inamullah Khan; Mohamad Bydon; Anthony L Asher; Kristin R Archer
Journal:  Qual Life Res       Date:  2019-06-06       Impact factor: 4.147

2.  Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Authors:  Monique Hinchcliff
Journal:  Arthritis Rheumatol       Date:  2020-07-04       Impact factor: 10.995

3.  Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study.

Authors:  Elizabeth St Lezin; Matthew S Karafin; Roberta Bruhn; Dhuly Chowdhury; Lirong Qu; Walter Bialkowski; Scott Merenda; Pamela D'Andrea; Anne-Lyne McCalla; Lisa Anderson; Sheila M Keating; Mars Stone; Edward L Snyder; Donald Brambilla; Edward L Murphy; Philip J Norris; Joan F Hilton; Bryan R Spencer; Steven Kleinman; Jeffrey L Carson
Journal:  Transfusion       Date:  2019-03-18       Impact factor: 3.157

4.  Measurement invariance and general population reference values of the PROMIS Profile 29 in the UK, France, and Germany.

Authors:  Felix Fischer; Chris Gibbons; Joël Coste; Jose M Valderas; Matthias Rose; Alain Leplège
Journal:  Qual Life Res       Date:  2018-01-19       Impact factor: 4.147

5.  Use of PROMIS-29® in US Veterans: Diagnostic Concordance and Domain Comparisons with the General Population.

Authors:  Sherri L LaVela; Bella Etingen; Scott Miskevics; David Cella
Journal:  J Gen Intern Med       Date:  2019-05-29       Impact factor: 5.128

6.  Comparative Responsiveness of the PROMIS Pain Interference Short Forms With Legacy Pain Measures: Results From Three Randomized Clinical Trials.

Authors:  Chen X Chen; Kurt Kroenke; Timothy Stump; Jacob Kean; Erin E Krebs; Matthew J Bair; Teresa Damush; Patrick O Monahan
Journal:  J Pain       Date:  2018-12-06       Impact factor: 5.820

7.  PROMIS®-29 v2.0 profile physical and mental health summary scores.

Authors:  Ron D Hays; Karen L Spritzer; Benjamin D Schalet; David Cella
Journal:  Qual Life Res       Date:  2018-03-22       Impact factor: 4.147

Review 8.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

9.  Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Authors:  Linda Kwakkenbos; Brett D Thombs; Dinesh Khanna; Marie-Eve Carrier; Murray Baron; Daniel E Furst; Karen Gottesman; Frank van den Hoogen; Vanessa L Malcarne; Maureen D Mayes; Luc Mouthon; Warren R Nielson; Serge Poiraudeau; Robert Riggs; Maureen Sauvé; Fredrick Wigley; Marie Hudson; Susan J Bartlett
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

10.  Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?

Authors:  Tracy M Frech; John M VanBuren; Emily Startup; Shervin Assassi; Elana J Bernstein; Flavia V Castelino; Lorinda Chung; Chase Correia; Jessica K Gordon; Faye N Hant; Laura Hummers; Dinesh Khanna; Nora Sandorfi; Ami A Shah; Victoria K Shanmugam; Virginia Steen; Luke Evnin
Journal:  Clin Rheumatol       Date:  2020-10-23       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.